

15 March 2022

Summary of the Risk Assessment and Risk Management Plan (consultation version) for Licence Application No. DIR 188

Introduction

The Gene Technology Regulator (the Regulator) has received a licence application for the intentional release of a genetically modified organism (GMO) into the environment. It qualifies as a limited and controlled release application under the *Gene Technology Act 2000* (the Act). The Regulator has prepared a Risk Assessment and Risk Management Plan (RARMP) for this application, which concludes that the proposed field trial poses negligible risks to human health and safety and the environment. Licence conditions have been drafted for the proposed field trial. The Regulator invites submissions on the RARMP, including draft licence conditions, to inform the decision on whether or not to issue a licence.

The application

| Applicant | Nuseed Pty Ltd |
|----------------------------|--|
| Project title | Limited and controlled release of canola and Indian mustard genetically modified for altered oil content and herbicide tolerance |
| Parent organisms | Canola (Brassica napus L.) |
| | Indian mustard (<i>Brassica juncea</i> (L.) Czern. & Coss.) |
| Introduced genes | Seven genes involved in biosynthesis pathway for long-chain polyunsaturated fatty acids: |
| | ● <i>Lackl-</i> Δ12D from yeast <i>Lachancea kluyveri</i> |
| | Picpa- ω3D from yeast Pichia pastoris |
| | Micpu-∆6D from microalga Micromonas pusilla |
| | Pyrco-Δ6E from microalga Pyramimonas cordata |
| | Pavsa-Δ5D from microalga Pavlova salina |
| | Pyrco-Δ5E from microalga Pyramimonas cordata |
| | Pavsa-Δ4D from microalga Pavlova salina |
| | One selectable marker gene that confers herbicide tolerance: |
| | pat gene from soil bacterium Streptomyces viridochromogenes for glufosinate tolerance |
| Proposed locations | Up to 20 trial sites per year to be selected from 96 possible local government areas in New South Wales, Victoria and Queensland |
| Proposed release size | Up to 150 ha per year |
| Proposed period of release | From November 2022 to December 2027 |
| Principal purpose | To evaluate the altered oil content trait under field conditions |

Risk assessment

The risk assessment concludes that risks to the health and safety of people, or the environment, from the proposed release are negligible. No specific risk treatment measures are required to manage these negligible risks.

The risk assessment process considers how the genetic modification and proposed activities conducted with the GMOs might lead to harm to people or the environment. Risks are characterised in relation to both the seriousness and likelihood of harm, taking into account current scientific/technical knowledge, information in the application (including proposed limits and controls) and relevant previous approvals. Both the short- and long-term impacts are considered.

Credible pathways to potential harm that were considered included exposure of people or desirable animals to the GM plant material, potential for persistence or dispersal of the GMOs, and transfer of the introduced genetic material to canola, Indian mustard and related plants outside the field trial. Potential harms associated with these pathways included toxicity or allergenicity to people, toxicity to desirable animals, and environmental harms due to weediness.

The principal reasons for the conclusion of negligible risks are that the proposed limits and controls will effectively minimise exposure to the GMOs, and there is no evidence to suggest the introduced genetic modifications would lead to harm to people or the environment.

Risk management

The risk management plan describes measures to protect the health and safety of people and to protect the environment by controlling or mitigating risk. The risk management plan is given effect through licence conditions. Draft licence conditions are detailed in Chapter 4 of the RARMP.

As the level of risk is considered negligible, specific risk treatment is not required. However, since this is a limited and controlled release, the draft licence includes limits on the size, location and duration of the release, as well as controls to prohibit the use of GM plant material in commercial human food or animal feed, to minimise dispersal of the GMOs or GM pollen from the trial sites, to transport the GMOs in accordance with the Regulator's guidelines, to destroy GMOs at the end of the trial and to conduct post-harvest monitoring at the trial sites to ensure the GMOs are destroyed.